The MEMUMAB (memory B Cell-based human monoclonal antibodies) approach identifies pathogen-specific antibodies from B cells of recovered or vaccinated individuals and uses these as blueprints for the production of human antibodies for therapeutic application. The process can easily be adapted to various diseases or pathogenic variants.
During the one-year funding period the team and its partners, including Ascenion, will evaluate MEMUMAB’s commercial potential and feasibility in order to provide a sound basis for deciding on further development.
The GO-Bio initial programme was initiated by the German Federal Ministry of Education and Research (BMBF) to support very early commercialization ideas from the drawing board. In the context of this programme, Ascenion is also building a dedicated ‘Life Science Digital Hub’, an auxiliary module sponsored as well by GO-Bio initial, to help scientists advance their ideas and apply for GO-Bio initial grants.
Further information:
- Contact Rebecca Engels at Ascenion to learn more about funding opportunities if you’re working on an early-stage project that is potentially commercially attractive.
- See TWINCORE’s press release to learn more about the MEMUMAB funding